Targeting Orexin to Treat Nicotine Dependence
NCT03999099
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Nicotine Dependence
Interventions
DRUG:
Suvorexant 20 mg
DRUG:
Suvorexant 10 mg
DRUG:
Placebo oral tablet
Sponsor
Mclean Hospital